MedTrace Logo

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors

NCT03917758 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-11-03

No results posted yet for this study

Summary

Subjects treated with Canagliflozin, Dapagliflozin and Empagliflozin obtained improvement on blood pressure values, body weight and cardiovascular mortality but pathophysiological explanations of these effects are not yet known.

Conditions

  • Diabetes Mellitus, Type 2
  • Arterial Hypertension
  • Body Weight Changes

Interventions

DRUG

SGLT2 inhibitor

Start of the treatment with SGLT2i.

Sponsors & Collaborators

  • University of Turin, Italy

    lead OTHER

Principal Investigators

  • Mauro M Maccario, MD · Endocrinology, Diabetology and Metabolism; University of Turin

  • Ezio E Ghigo, MD · Endocrinology, Diabetology and Metabolism; University of Turin

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-10
Primary Completion
2020-07-30
Completion
2020-10-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03917758 on ClinicalTrials.gov